Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostic Services…
CorWave, a medical device company, announces the world’s first implantation in a patient of its Left Ventricular Assist System (LVAS), the first heart pump based on breakthrough wave membrane technology. The procedure was performed by the team at St Vincent’s…
A global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has developed a dual-active material science technology engineered to simultaneously control moisture and oxygen. This technology is designed to provide a singular solution…
Petspan, the veterinary telemedicine division of longevity health company Healthspan, today announced the launch of the industry’s first remote-care protocol delivering rapamycin therapy to cats diagnosed with hypertrophic cardiomyopathy (HCM). Our HCM protocol gives cat parents access to a therapy supported by…
OhioGuidestone, Ohio’s leader in community behavioral healthcare, announced today the expansion of its partnership with Greenspace Health, extending the use of its Measurement-Based Care (MBC) technology across the organization’s behavioral health services to further improve their quality of care, client outcomes…
A precision cardiovascular medicine company with a pioneering technology at the intersection of epigenetics and AI, today announced an agreement with AGEPHA Pharma that will enable the validation of a precision-guided approach to treating inflammation-driven coronary heart disease (CHD). Specifically, AGEPHA Pharma…
A technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, Tempus Next, into breast cancer. Since its launch in 2024, Tempus Next has screened thousands of…
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber has over 30 years of financial and strategic leadership experience in…
AI Platform Evidently Announces Partnership With Allina Health Clinical data intelligence platform Evidently is announcing an extended partnership with Allina Health, under which Evidently’s AI system will process millions of patient encounters each year to reduce clinicians’ cognitive workloads while elevating quality…
A pioneer in cardiac treatment for microvascular disease, today announced that the U.S. Food & Drug Administration (FDA) has granted its technology an Investigational Use Exemption (IDE), allowing the pivotal clinical trial to begin in U.S. hospitals. CorFlow will now…